8-K: Aprea Therapeutics Announces Preliminary Cash Position of $21.6 Million for Fiscal Year 2023

Aprea Therapeutics reports a preliminary cash balance of approximately $21.6 million as of December 31, 2023, pending final audit.

Summary

• Aprea Therapeutics has released preliminary, unaudited estimates of its cash position.
• The company estimates it had approximately $21.6 million in cash, cash equivalents, and restricted cash as of December 31, 2023.
• These figures are preliminary and subject to change upon completion of the company's year-end financial close process.
• The company's independent accounting firm has not audited or reviewed these preliminary results.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the document provides a preliminary cash balance, which is neither positive nor negative on its own. The lack of an audit introduces some uncertainty.

Positives

• The company has provided an early indication of its cash position, offering some transparency to investors.

Negatives

• The reported cash balance is preliminary and unaudited, meaning it could change.
• The company's independent accounting firm has not reviewed the preliminary results, adding uncertainty.

Risks

• The final audited cash balance may differ from the preliminary estimate of $21.6 million.
• The lack of an audit or review by the company's accounting firm introduces uncertainty about the accuracy of the preliminary figures.

Future Outlook

The company will complete its year-end financial close process, which may result in changes to the preliminary cash balance.

Management Comments

• Oren Gilad, Ph.D., President and Chief Executive Officer, signed the report on behalf of Aprea Therapeutics.

Industry Context

This announcement is typical for a biotech company providing a preliminary update on its cash position before the full financial results are released. It allows investors to have an early indication of the company's financial health.

Comparison to Industry Standards

• Many biotech companies provide preliminary cash updates before their full financial results are released.
• The $21.6 million cash position will be compared to other similar stage biotech companies to assess Aprea's financial runway.
• Companies like Xencor and Iovance Biotherapeutics, which are also in the clinical stage, are often used as benchmarks for cash burn and runway.

Stakeholder Impact

• Shareholders will be interested in the company's cash position as it impacts the company's ability to fund operations.
• Employees may be interested in the company's financial health as it relates to job security.

Next Steps

• The company will complete its year-end financial close process.
• The company will release its full audited financial results at a later date.

Key Dates

Keywords

cash, preliminary, unaudited, financial, Aprea Therapeutics, balance, results